Search Results 131-140 of 17472 for ulcerative colitis

  1. A Study Comparing the Long Term Safety of Entyvio (Vedolizumab) to Other Biologic Agents in Patients with Ulcerative Colitis or Crohn's Disease - Mayo Clinic

    The purpose of this study is to assess the long-term safety of vedolizumab versus other biologic agents in participants with Ulcerative Colitis or Crohn's ...

  2. Pyoderma gangrenosum - Symptoms and causes - Mayo Clinic

    It's often seen in people who have autoimmune diseases, such as ulcerative colitis, Crohn's disease and arthritis. And some studies suggest that it may be ...

  3. A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC) - Mayo Clinic

    A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC). Print details.

  4. A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis Patients Who Are Naive to TNF Inhibitors - Mayo Clinic

    A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis Patients Who Are Naive to TNF Inhibitors.

  5. A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001) - Mayo Clinic

    A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001) · Overview.

  6. A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC) - Mayo Clinic

    A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC) · More about research at Mayo Clinic · Mayo ...

  7. A Study to Evaluate the Effectiveness and Safety of Risankizumab in Subjects with Moderately-to-Severely Active Ulcerative Colitis - Mayo Clinic

    A Study to Evaluate the Effectiveness and Safety of Risankizumab in Subjects with Moderately-to-Severely Active Ulcerative Colitis. Print details. Share ...

  8. Inflammatory bowel disease (IBD) - Doctors and departments - Mayo Clinic

    ... ulcerative colitis. Mayo Clinic researchers conducted the first clinical study of mesalamine and discovered that genetic differences significantly affected ...

  9. How obesity affects IBD management and patient outcomes: Q&A with Amanda M. Johnson, M.D. - Mayo Clinic

    Prospective disease evaluation, improved control of confounding factors, and obesity measures that reflect visceral adipose tissue are needed to understand ...

  10. Inflammatory bowel disease (IBD) - Doctors and departments - Mayo Clinic

    ... ulcerative colitis. Mayo Clinic researchers conducted the first clinical study of mesalamine and discovered that genetic differences significantly affected ...